Clinical and Applied Thrombosis/Hemostasis (Aug 2022)

The Drug Coated Balloon-Only Strategy for Treatment of de Novo Left Main Coronary Artery Bifurcation Lesion: Stentless Strategy

  • Hengdao Liu,
  • Yanyan Zhao,
  • Yang Lu,
  • Shilong Zhou,
  • Yubin Zhang,
  • Junwei Zhao,
  • Huilin Yang,
  • Junhui Xing,
  • Ruihan Feng,
  • XiaoFei Xue,
  • Hailong Tao,
  • Ruipeng Song,
  • Heping Gu

DOI
https://doi.org/10.1177/10760296221118489
Journal volume & issue
Vol. 28

Abstract

Read online

The study aimed to evaluate the efficacy and safety of drug coated balloon-only strategy (DCB-only) in the treatment of de novo left main coronary artery (LM) bifurcation lesions. 85 patients were enrolled in this study and classified them into two groups: DCB-only group (n = 36) and DES group (n = 49). The MLD of target vessels was measured before and immediately after percutaneous coronary intervention (PCI) and late luminal loss (LLL) were also calculated. And the occurrence of major adverse cardiovascular events (MACE) was also evaluated. Compared with that before PCI, the MLD of target lesions significantly increased immediately after PCI ( P .05). The use of DCB-only to treat de novo LM bifurcation lesions is effective and relatively safe, which provides new ideas for the treatment of LM coronary artery bifurcation lesions in the future.